Natural Product (NP) Details
| General Information of the NP (ID: NP6356) | |||||
|---|---|---|---|---|---|
| Name |
Vanillic acid
|
||||
| Synonyms |
Vanillic acid; 4-HYDROXY-3-METHOXYBENZOIC ACID; 121-34-6; Acide vanillique; Benzoic acid, 4-hydroxy-3-methoxy-; p-Vanillic acid; 3-Methoxy-4-hydroxybenzoic acid; Vanillate; m-Anisic acid, 4-hydroxy-; Protocatechuic acid, 3-methyl ester; 4-hydroxy-3-methoxy-Benzoic acid; UNII-GM8Q3JM2Y8; 4-Hydroxy-3-methoxybenzoate; NSC 3987; MFCD00002551; NSC 674322; GM8Q3JM2Y8; CHEMBL120568; CHEBI:30816; 4-hydroxy-3-methoxy benzoic acid; NSC674322; VA; VA (VAN); 4-Hydroxy-3-methoxybenzoic acid, 97+%; VNL; 4-hydroxy-m-Anisic acid; EINECS 204-466-8; BRN 2208364; Vanillinsaure; p-Vanillate; Vanilic acid; AI3-19542; Vanillic Acid,(S); 4-hydroxy-m-Anisate; Vanillic acid (M2); Vanillic acid, 97%; PubChem19485; ACMC-1BPT2; bmse000486; bmse000614; bmse010205; WLN: QVR DQ CO1; 3-Methoxy-4-hydroxybenzoate; SCHEMBL26179; MLS000574833; 4-hydroxy-3-methoxy-Benzoate; 4-Hydroxy-3-methoxybenzoicacid; Vanillic acid, >=97%, FG; 4-hydroxy-3methoxy benzoic acid; DTXSID6059522; 4-hydroxyl-3-methoxybenzoic acid; NSC3987; 4- hydroxy-3-methoxybenzoic acid; HMS2197E16; Protocatechuic acid 3-methyl ester; ZINC338275; HY-N0708; NSC-3987; STR02334; ANW-17590; BBL011982; BDBM50337364; s5343; SBB008280; STL163472; AKOS000113195; CCG-266343; MCULE-2667517874; MP-2220; NSC-674322; NCGC00247610-01; AC-11841; AK-32998; BP-13246; SMR000156289; ST086485; SY001450; DB-003804; Vanillic acid, purum, >=97.0% (HPLC); AM20050239; CS-0009728; FT-0650155; C06672; Vanillic acid, Vetec(TM) reagent grade, 97%; 198598-EP2277877A1; Q419672; Q-201921; Z1741973874; Vanillic acid, certified reference material, TraceCERT(R); 3E9555E5-85F5-4FCE-A429-5182E959C6A3
Click to Show/Hide
|
||||
| Species Origin | Angelica sinensis ... | Click to Show/Hide | |||
| Angelica sinensis | |||||
| Disease | Asthma [ICD-11: CA23] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.096
MDCK Permeability
-4.774
PAMPA
+++
HIA
- -
Distribution
VDss
-0.671
PPB
67.7%
BBB
- - -
Metabolism
CYP1A2 inhibitor
- - -
CYP1A2 substrate
- - -
CYP2C19 inhibitor
- - -
CYP2C19 substrate
- - -
CYP2C9 inhibitor
- - -
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
- -
HLM Stability
- - -
Excretion
CLplasma
3.04
T1/2
1.978
Toxicity
DILI
+
Rat Oral Acute Toxicity
- -
FDAMDD
- -
Respiratory
+
Human Hepatotoxicity
-
Ototoxicity
-
Drug-induced Nephrotoxicity
-
Drug-induced Neurotoxicity
-
Hematotoxicity
-
Genotoxicity
- -
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C8H8O4
|
||||
| PubChem CID | |||||
| Canonical SMILES |
COC1=C(C=CC(=C1)C(=O)O)O
|
||||
| InChI |
1S/C8H8O4/c1-12-7-4-5(8(10)11)2-3-6(7)9/h2-4,9H,1H3,(H,10,11)
|
||||
| InChIKey |
WKOLLVMJNQIZCI-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 121-34-6
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| SymMap ID | |||||
| TCMSP ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Adverse Effect can be Decreased by This NP | ||||||
| Doxorubicin | Solid tumour/cancer | Click to Show/Hide the Molecular Data of This Drug | ||||
| Decreasing Adverse Drug Reaction | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| Molecule(s)
Regulation |
Down-regulation | Expression | TLR4 | Molecule Info |
Pathway MAP
|
|
| In-vivo Model | Male Wistar albino rats weighing 200 +/- 20 g were used in this study. | |||||
| Experimental
Result(s) |
VA exerts cardioprotective effects against DOX-induced cardiotoxicity by decreasing oxidative stress and biomarkers of cardiotoxicity, suppression of TLR4 signaling and consequently inflammation pathway. | |||||
| Target and Pathway | ||||
|---|---|---|---|---|
| Target(s) | CCAAT/enhancer-binding alpha (CEBPA) | Molecule Info | [3] | |
| PPAR-gamma (PPARG) | Molecule Info | [3] | ||
| KEGG Pathway | PPAR signaling pathway | Click to Show/Hide | ||
| 2 | AMPK signaling pathway | |||
| 3 | Osteoclast differentiation | |||
| 4 | Huntington's disease | |||
| 5 | Pathways in cancer | |||
| 6 | Transcriptional misregulation in cancer | |||
| 7 | Thyroid cancer | |||
| NetPath Pathway | IL1 Signaling Pathway | Click to Show/Hide | ||
| 2 | TGF_beta_Receptor Signaling Pathway | |||
| 3 | Leptin Signaling Pathway | |||
| Panther Pathway | CCKR signaling map ST | Click to Show/Hide | ||
| Pathway Interaction Database | Noncanonical Wnt signaling pathway | Click to Show/Hide | ||
| 2 | Calcineurin-regulated NFAT-dependent transcription in lymphocytes | |||
| 3 | Signaling events mediated by HDAC Class I | |||
| 4 | RXR and RAR heterodimerization with other nuclear receptor | |||
| 5 | Regulation of retinoblastoma protein | |||
| Reactome | PPARA activates gene expression | Click to Show/Hide | ||
| 2 | Transcriptional regulation of white adipocyte differentiation | |||
| 3 | Nuclear Receptor transcription pathway | |||
| WikiPathways | Wnt Signaling Pathway Netpath | Click to Show/Hide | ||
| 2 | Nuclear Receptors in Lipid Metabolism and Toxicity | |||
| 3 | Differentiation of white and brown adipocyte | |||
| 4 | Regulation of Lipid Metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha) | |||
| 5 | Transcriptional Regulation of White Adipocyte Differentiation | |||
| 6 | Adipogenesis | |||
| 7 | SREBP signalling | |||
| 8 | Nuclear Receptors | |||
